



Freidja et al. Cardiovascular Diabetology 2014, 13:55
http://www.cardiab.com/content/13/1/55ORIGINAL INVESTIGATION Open AccessAGEs breaking and antioxidant treatment
improves endothelium-dependent dilation without
effect on flow-mediated remodeling of resistance
arteries in old Zucker diabetic rats
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Background: A chronic increase in blood flow in resistance arteries is associated with increased lumen diameter
(outward remodeling) and improved endothelium (NO)-mediated relaxation. Flow-mediated remodeling of resistance
arteries is essential for revascularization in ischemic diseases. Nevertheless, it is impaired in 12 to 24-month old rats and
in young Zucker Diabetic Fatty (ZDF) rats due to advanced glycation end products (AGEs) and oxidative stress. As type
2 diabetes occurs preferentially in older subjects we investigated flow-mediated remodeling and the effect of the AGEs
breaker ALT-711 associated or not to the antioxidant TEMPOL in one-year old lean (LZ) and ZDF rats.
Methods: Mesenteric resistance arteries were exposed to high (HF) or normal blood flow (NF) in vivo. They were
collected after 2 weeks for in vitro analysis.
Results: In LZ rats, diameter expansion did not occur despite a significant increase in blood flow in HF arteries.
Nevertheless, endothelium-mediated relaxation was higher in HF than in NF arteries. ALT-711, alone or in combination
with TEMPOL, restored outward remodeling in HF arteries in association with AGEs reduction. TEMPOL alone had
no effect. ALT-711, TEMPOL or the combination of the 2 drugs did not significantly affect endothelium-mediated
relaxation in HF and NF arteries.
In ZDF rats, diameter did not increase despite the increase in blood flow and endothelium-mediated relaxation
was further decreased in HF arteries in association with AGEs accumulation and excessive oxidative stress. In
both NF and HF arteries, endothelium-mediated relaxation was lower in ZDF than in LZ rats. ALT-711, TEMPOL
or their combination did not improve remodeling (diameter equivalent in HF and NF arteries). In parallel, they
did not reduce AGEs level and did not improve MMPs activity. Nevertheless, ALT-711 and TEMPOL partly improved
endothelium-mediated relaxation through a reduction of oxidative stress and the association of ALT-711 and TEMPOL
fully restored relaxation to the level found in LZ rats.
Conclusions: ALT-711 did not improve outward remodeling in mature ZDF rats but it reduced oxidative stress and
consequently improved endothelium-dependent relaxation. In mature LZ rats, ALT-711 improved outward remodeling
and reduced AGEs level. Consequently, AGEs breaking is differently useful in ageing whether it is associated with
diabetes or not.* Correspondence: daniel.henrion@inserm.fr
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The frequency of type 2 diabetes increases in most coun-
tries so that it is now a major health problem [1] associ-
ated with an increased risk of cardiovascular events [2,3].
As the microcirculation provides nutrient and oxygen to
distal tissues, damages affecting resistance arteries induce
ischemic disorders. Indeed, resistance arteries have a key
role in the control of local blood flow. They are able adapt
to chronic increases in blood flow, leading to diameter
enlargement and improved endothelium (nitric oxide,
NO)-dependent relaxation [4]. Flow-mediated outward
remodeling of resistance arteries is the driving force
for collateral arteries growth following obstruction of a
large artery [5,6]. Indeed, after occlusion of a conduit
artery, blood flow is redirected through adjacent preex-
isting collateral vessels, which are consequently submit-
ted to increased shear stress. In contrast to angiogenesis,
which is initiated by ischemia, flow-mediated diameter ex-
pansion occurs in regions of high-fluid shear stress [7].
Following a chronic increase in shear stress, an inflamma-
tory response associated with oxidative stress occurs lead-
ing to activation of matrix metalloproteinases (MMPs)
and then by a diameter expansion [8,9].
We have previously shown that outward remodeling
of resistance arteries is impaired in young (3-month
old) Zucker Diabetic Fatty (ZDF) rats, a model of type
2 diabetes, in combination with a strong reduction in
endothelium-mediated dilation [10]. In addition, we
found that advanced glycation end products (AGEs)
are involved in this dysfunction observed in type 2 dia-
betic rats as flow-mediated remodeling was recovered
in young ZDF rats treated with the AGEs breaker ALT-
711 [6]. In 3-month old ZDF rats, AGEs cross-links
prevent MMPs activation and induce oxidative stress
with increased 3-nitrotyrosine and NADPHoxidase
subunit (p67) level [6]. The main limitation of these
previous works is that diabetic rats were very young
and thus submitted to a very short period of diabetes
(a few weeks). AGEs are generated by non-enzymatic
glycation of structural proteins by glucose, a process
accompanying normal aging and occurring at an accel-
erated rate in diabetes [11,12]. As the frequency of
type 2 diabetes increases with age and vascular dam-
ages associated with diabetes develop over time [3] we
investigated flow-mediated remodeling in older ZDF
rats and assessed the ability of ALT-711, alone or in
combination with an antioxidant, to improve outward
remodeling and endothelium-mediated dilation in type
2 diabetic rats. We used 12-months old rats, which is
the half life expectancy of the non-diabetic rat.
We investigated flow-mediated remodeling using a
model allowing the comparison of resistance arteries
chronically submitted to high or normal blood flow
levels, under similar physiological conditions in the samevascular bed in vivo [6]. ZDF and LZ rats were treated
with the AGE-breaker ALT-711, the antioxidant TEM-
POL or a combination of ALT-711 and TEMPOL.
Material and methods
Animals
Twelve-month old adult male ZDF and lean Zucker (LZ)
rats (Charles River, L’Arbresles, France) were anesthetized
(Isoflurane, 2.5%) and submitted to surgery in order to
modify blood flow as previously described [13,14]. Briefly,
three consecutive first-order mesenteric arteries were
used. Ligatures (7–0 silk surgical thread) were applied to
second-order branches of the first and third arteries, as
shown in Figure 1. The artery located between two ligated
arteries was designated as an HF (high flow) artery. Other
arteries located at distance of the ligated arteries were
used as control (normal flow, NF) arteries. Rats were
treated with buprenorphine (Temgesic®; 0.1 mg/kg, s.c.)
before and after surgery. Rats were treated with 4,5-
dimethyl-3-phenacylthiozolium chloride (ALT-711, 10 mg/kg
per day, ip, n = 10). Treatment started one week before
surgery. Another group of rats was treated with the anti-
oxidant 4-hydroxy-2, 2,6,6-tetramethyl piperidinoxyl (TEM-
POL, 10 mg/kg per day, gavage, n = 10) and a third group
with the combination of ALT-711 and TEMPOL (n = 10).
Control groups received the solvents only. The total dur-
ation of the treatments was 3 weeks.
Fourteen days after surgery, the rats were anesthetized
(Isoflurane, 2.5%) and the right femoral artery catheter-
ized for blood pressure measurement [15]. Blood flow
was measured in HF and NF arteries using a Transonic ®
flow probe [16]. In short, a medial laparotomy was per-
formed and a section of the ileum was extracted and
spread over a gauze swab that had been dampened with
a sterile physiological salt solution. The mesenteric ar-
tery was dissected free of fat and connective tissue. By
use of a micromanipulator, a transit-time ultrasonic flow
probe (0.5-mm V series, Transonic Systems) was placed
around the artery. Flow was determined with a T106
flow-meter (Transonic Systems). A zero-flow reading
was obtained by softly clamping the artery. Then, flow
was measured and recorded (Biopac MP100) over a
period of 10 minutes (each flow value was the average of
at least 3 minutes of recording). Rats were then eutha-
nized by CO2 inhalation, the gut excised and the mesen-
teric arteries gently dissected. HF and NF arteries from
each rat were isolated and divided into several segments
used respectively for pressure-diameter relationship meas-
urement, pharmacology and biochemistry. Before euthan-
asia, glycaemia was quantified on a sample of arterial
blood using a glucometer [4].
The procedure followed in the care and euthanasia of
the study animals complied with European Community
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Figure 1 Experimental model: Schematic representation of the mesenteric circulation in rats and location of the ligations (arrows) of
second-order mesenteric artery branches. The artery located between two ligated vessels was submitted chronically too high flow (HF) artery.
Equivalent non-ligated arteries located at a distance from the ligatures had normal flow (NF). Rats were treated with ALT-711 plus TEMPOL
(Alt + T) or not. The bargraph shows blood flow measurements obtained using a Transonic ® flow probe in HF and NF arteries of LZ and ZDF
rats 14 days after ligation. Values are mean ± SEM (n = 4 to 6 per group). *P < 0.05, HF versus NF.
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6422) and the Principles of Laboratory Animal Care
(NIH publication no. 85–23, revised 1985; http://grants1.
nih.gov/grants/olaw/references/phspol.htm). The protocol
was approved by the Committee on the Ethics of Animal
Experiments of the “Pays de la Loire” Region (permit #
CEEA PdL 2008.10).
Pressure-diameter relationship in HF and NF arteries
Segments of arteries were cannulated at both ends, mounted
on a video-monitored perfusion system (LSI, Burlington,
VT) and perfused and superfused with a Ca2+-free physio-
logical salt solution (PSS) containing ethylene glycol tetra-
acetic acid (EGTA, 2 mmol/L) and sodium nitroprusside
(SNP, 10 μmol/L) [17]. Arterial segments were then submit-
ted to a stepwise increase in pressure (10 to 150 mmHg) in
order to determine arterial passive diameter [18]. Data were
recorded using a Biopac data acquisition system (La Jolla,
CA, USA) and analyzed with Acqknowledge® software.Pharmacological profile of isolated HF and NF arteries
Other arterial segments (2 mm long) were dissected and
mounted on a wire myograph (DMT, Aarhus, DK) [19].
Two tungsten wires (25 μm in diameter) were inserted
into the lumen of the arteries and respectively fixed to a
force transducer and a micrometer. Arteries were bathed
in a PSS of the following composition (mM): 130, NaCl;
15, NaHCO3; 3.7, KCl; 1.2 KH2PO4; 1.2, MgSO4; 11, glu-
cose; 1.6, CaCl2; and 5, HEPES, pH 7.4, PO2 160 mmHg,
PCO2 37 mmHg. Wall tension was applied as previously
described [20]. Viability of the arterial segments was
tested using a potassium-rich solution (KCl, 80 mmol/L)
followed by a concentration-response curve (CRC) to
phenylephrine (Phe, 0.001 to 10 μmol/L, 3 min between
2 concentrations, unless a plateau is not reached). A
CRC to acetylcholine (ACh, 0.001 to 10 μmol/L, 2 min
between 2 concentrations, unless a plateau is not
reached) was performed after a precontraction induced
by phenylephrine to approximately 50% of the maximal
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to ACh (0.001 to 10 μmol/L) was performed in the pres-
ence of L-NAME (100 μmol/L) or in the presence of
superoxide dismutase (120 U/ml) and catalase (80 U/ml).
Finally, a CRC to sodium nitroprusside (SNP, 0.001 to
10 μmol/L, 2 min between 2 concentrations, unless a plat-
eau is not reached) was performed.
Western blot analysis
The remaining segments of NF and HF arteries were
used for western-blot analysis. Proteins (25 μg total pro-
tein from each sample) were separated by SDS-PAGE
using a 4% stacking gel, followed by a 10% running gel.
Proteins were detected with specific antibodies (Trans-
duction Laboratories, eNOS 1:1000; AGE 1:100; MnSOD,
1:1000; CuZnSOD, 1:1000; p67phox, 1:1000 and beta-
actin 1:1000). Protein expression was visualized using the
ECL Plus chemiluminescence kit (Amersham) [21].
Immunhistological analysis of 3-nitrotyrosine
As previously described [22], segments of arteries were
mounted in embedding medium (Tissu-Tek, Miles, Inc),
frozen in isopentane pre-cooled in liquid nitrogen, and
stored at −80°C. Arterial segments were then pulverised
in liquid nitrogen. The powder obtained was resus-































Figure 2 Body weight and blood glucose in rats: Body weight and blo
Zucker rats (ZDF) in control condition (CONT) or treated with the ant
mixture of TEMPOL and ALT-711 (T + A). Mean ± SEM is presented (n =
groups included). #P < 0.05, ZDF compared to LZ rats (intragroup comparisTris–HCl pH 7.4, 1% sodium dodecyl sulfate, 1 mmol/L
sodium orthovanadate, and protease inhibitors. Vessel ex-
tracts were incubated in this buffer on ice for 30 minutes
and then centrifuged (14 000 rpm, 15 minutes, 10°C). The
detergent soluble supernatant fractions were retained, and
the protein concentration of the samples was determined
using a Micro BCA Protein Assay Kit (Pierce). Proteins
(15 μg total protein from each sample) were separated by
SDS-PAGE and transferred to nitrocellulose membranes.
The membranes were incubated with the primary anti-
body against anti-3-nitro-tyrosine (Upstate and used at a
concentration of 20 g/mL) [23]. Fluorescence staining was
visualized using confocal microscopy and image analysis
(Histolab, Microvision, France) [4].
In situ zymography
MMPs activity was determined by in situ zymography as
previously described [6]. Isolated arterial segments were
incubated for 15 min with angiotensin II (100 nmol/L)
in PSS. The arteries were then quickly embedded verti-
cally in Tissue-Tek and frozen. The frozen sections
(7 μm thick) were incubated over night (37°C) with a
fluorogenic gelatin substrate (Molecular Probes) dis-
solved to 25 μg/mL in zymography buffer (50 mmol/L
Tris–HCl, 10 mmol/L CaCl2, and protease inhibitor
cocktail, pH 7.4) [24]. The gelatin with a fluorescent tagCONT TEMP ALT T+A





od glucose measured in lean Zucker (LZ) and diabetic fatty
ioxidant TEMPOL (T), the AGE-breaker ALT-711 (ALT) or the
10 per group). *P < 0.05, ZDF compared to LZ rats (all treatment
on).
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activity. In situ gelatinolysis was revealed by the ap-
pearance of fluorescence visualized and quantified
using confocal microscopy. In control experiments,
sections were incubated with metalloproteinase inhib-
itors (1,10-phenanthroline and Ethylenediaminetetra-
acetic acid (EDTA).
Statistical analysis
Results were expressed as a mean ± SEM. Significance of


















































































Figure 3 Flow-mediated remodeling in ZDF and LZ rats: Changes in d
and NF mesenteric resistance arteries isolated from lean Zucker (LZ,
curves to acetylcholine were performed in NF (C) and HF (D) arteries in th
mediated relaxation (E) and the inhibitory effect of L-NAME on acetylcholine-me
Mean ± SEM is presented (n = 10 per group). *P < 0.05, HF arteries compared to Nway ANOVA followed by the Bonferroni post hoc test.
Values of P < 0.05 or lower were considered to be statis-
tically significant.
Results
ZDF rats have a significantly lower body weight and
greater blood glucose compared to LZ rats (Figure 2).
Blood flow measured in the HF artery was not significantly
higher than in the NF artery in both rat strains (Figure 1).
In both LZ and ZDF rats, the diameter of the HF ar-













































































iameter (A-B) in response to stepwise increases in pressure in HF
A) and diabetic fatty Zucker rats (ZDF, B). Concentration-response
e presence or absence of L-NAME (100 μmol/L). Emax for acetylcholine-
diated relaxation (F) were calculated from the curves shown in C and D.
F arteries. #P < 0.05, ZDF compared to LZ.
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thelium (acetylcholine)-mediated relaxation was greater
in HF arteries (Figure 3C) than in NF arteries (Figure 3D)
but this was not the case in ZDF rats. This was confirmed
by the calculated Emax for acetylcholine-mediated relax-
ation (Figure 3E). In both NF and HF arteries, acetylcholine-
mediated relaxation was lower in ZDF than in LZ rats
(Figure 3C-E). In LZ rats, L-NAME reduced acetylcholine-




















































































Figure 4 Flow-mediated remodeling after treatment with ALT-711: Ch
pressure in HF and NF mesenteric resistance arteries isolated from le
with ALT-711. Concentration-response curves to acetylcholine were perfo
L-NAME (100 μmol/L). Emax for acetylcholine-mediated relaxation (E) and the
were calculated from the curves shown in C and D. Mean ± SEM is presented
#P < 0.05, ZDF compared to LZ.ZDF rats, L-NAME reduced the relaxation in NF arteries
only (Figure 3C). The inhibitory effect of L-NAME was
lower in ZDF than in LZ rats in both NF and HF arteries
(Figure 3F).
In rats treated with ALT-711 arterial diameter was
higher in HF than in NF vessels in LZ rats (Figure 4A)
whereas no significant difference was observed between
HF and NF arteries in ZDF rats (Figure 4B). Nevertheless,


















































anges in diameter (A,B) in response to stepwise increases in
an Zucker (LZ, A) and diabetic fatty Zucker rats (ZDF, B) treated
rmed in NF (C) and HF (D) arteries in the presence or absence of
inhibitory effect of L-NAME on acetylcholine-mediated relaxation (F)
(n = 10 per group). *P < 0.05, HF arteries compared to NF arteries.
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also improved the inhibitory effect of L-NAME in ZDF
rats (Figure 4F). ALT-711 had no significant effect on
acetylcholine-mediated relaxation and on the the inhibi-
tory effect of L-NAME in NF and HF arteries isolated
from LZ rats.
The eNOS, MnSOD and CuZnSOD expression level,
reduced in ZDF rats compared to LZ rats, was not af-
fected by ALT-711 (Figure 5). On the other hand,
p67phox, gp91phox expression level was higher in ZDF
rats compared to LZ rats. ALT-711 reduced it to the
same level as in LZ animals (Figure 6A and B). This was
not significant for p22phox (Figure 6C). Consequently,
we tested functionally the effect of reactive oxygen spe-
cies on endothelium-dependent relaxation in resistance
arteries. Indeed, removing reactive oxygen species acutely
using SOD and catalase improved acetylcholine-mediated
relaxation in HF and NF vessels isolated from ZDF rats
with no change in LZ rats arteries (Figure 6D). These ex-
periments demonstrated that reactive oxygen species re-
duced acetylcholine-mediated relaxation in arteries of
ZDF rats. The effect of ALT-711 on oxidative stress was
further confirmed by the measurement of 3-nitro-tyrosine
in arteries (Figure 7). 3-nitro-tyrosine was greater in
ZDF than in LZ rats. TEMPOL, ALT-711 or their com-
bination significantly reduced 3-nitro-tyrosine level in
ZDF rats. Similarly, TEMPOL plus ALT-711 reduced
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Figure 5 Measurement of eNOS and SOD in mesenteric arteries: Dete
ZnSOD (C) in mesenteric resistance arteries isolated from lean Zucker (LZ)
Mean ± SEM is presented (n = 10 per group). *P < 0.05, ZDF versus LZ.Consequently, ZDF and LZ were treated chronically
with the antioxidant TEMPOL. In TEMPOL-treated LZ
and ZDF rats, we found no significant difference be-
tween HF and NF artery diameter (Figure 8A and B).
Acetylcholine-mediated relaxation was higher in HF
than in NF arteries in LZ rats, not in ZDF rats (Figure 8C,
D and E). L-NAME significantly reduced acetylcholine-
mediated relaxation in all groups (Figure 8C,D and F).
Thus, TEMPOL improved endothelium (NO)-dependent
relaxation in arteries of ZDF rats. This effect was similar
to that of ALT711 shown in Figure 4. Nevertheless, by
contrast with ALT711, TEMPOL did not improve flow-
mediated outward remodeling (no increase in HF arteries
diameter). Next, we treated ZDF and LZ rats with a com-
bination of ALT711 and TEMPOL.
In LZ rats treated with TEMPOL and ALT-711, the
HF artery diameter was significantly higher than in
NF vessels (Figure 9A). This was not observed in ZDF
rats (Figure 9B). Acetylcholine-mediated relaxation
was higher in HF than in NF arteries in LZ and in
ZDF rats (Figure 9C). Acetylcholine-mediated relax-
ation was not significantly different in LZ rats com-
pared to ZDF rats (Figure 9C,D and E). L-NAME
totally suppressed relaxation in all groups (Figure 9C
and D).
SNP-mediated dilation, which is independent of the
endothelium, was not significantly different in HF and NF
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Figure 6 Detection of NADPH-oxidase subunits in mesenteric arteries: Detection using Western-blot analysis of p67phox (A),
gp91phox (B) and p22phox (C) in mesenteric resistance arteries isolated from lean Zucker (LZ) and diabetic fatty Zucker rats (ZDF)
treated or not with ALT-711. The effect of SOD and catalase (SOD-cat) was tested on acetylcholine-induced relaxation (D) in NF and HF mesen-
teric arteries isolated from LZ and ZDF rats. *P < 0.05, ZDF versus LZ. #P < 0.05, ALT-711 compared to control (untreated).
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tion (Figure 10).
Advanced glycation end products (AGEs) were higher
in ZDF rat arteries than in LZ rat arteries (Figure 11).
Nevertheless, ALT-711 alone (data not shown) or in
association with TEMPOL did not reduce the level ofAGEs in ZDF rats whereas it decreased it significantly in
LZ rats (Figure 11).
As flow-mediated remodeling depends on MMPs ac-
tivity, we measured MMPs activation in arteries isolated
from LZ and ZDF rats. In LZ rats, angiotensin II signifi-
cantly increased MMPs activity as assessed by in situ
LZ ZDF




































Figure 7 Detection of 3-nitrotyrosine in mesenteric arteries: 3-nitrotyrosine detection using immunofluorescence was performed in thin sections
of NF, or HF arteries using confocal microscopy. Arteries were isolated from LZ rats or from ZDF rats treated or not with ALT-711, Tempol or Tempol +
ALT-711. Image contrast and brightness were increased by 10% in each image to improve visibility. Bargraph: Quantification of 3-nitrotyrosine was per-
formed using image density analysis (3–4 arterial sections per artery and 10 rats per group). Mean ± SEM is presented. *P < 0.05, treated versus untreated.
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rats angiotensin II induced no significant increase in
MMPs activity (Figure 12). The treatment with ALT-711
did not improve the activation of MMPs by angiotensin
II. Thus, MMPs activity remained reduced in ZDF rats
despite a treatment with ALT711 in association with the
antioxidant TEMPOL or not.
Discussion
In the present study, we found that in one-year old rats,
type 2 diabetes impaired not only endothelium-dependent
dilation but also the ability of resistance arteries to re-
model in response to a chronic increase in blood flow.
Ongoing treatment with the AGE-breaker ALT-711 failed
to restore flow-mediated remodeling in ZDF rats whereas
this treatment improved remodeling in LZ rats. Neverthe-
less, ALT-711 improved NO-dependent relaxation of mes-
enteric resistance arteries through reduction of oxidative
stress without change in AGEs level.
Pathophysiology of flow-mediated remodeling
A chronic increase in blood flow (shear stress) in resist-
ance arteries induces outward hypertrophic remodelingand improves endothelium-dependent dilation [4,14,25].
This is essential to adjust organ perfusion in development
[26], pregnancy [27], exercise [28] or in response to
vasodilator treatments [29]. Furthermore, flow-mediated
remodeling of resistance arteries plays a key role in revas-
cularization after occlusion of a large artery as it allows
collateral arteries growth and takes part in arteriogenesis
[30]. The model used in the present work has the advan-
tage of a vascular bed composed of multiple similar resist-
ance arteries enabling study of the effects of blood flow on
the arterial diameter independent of changes in blood
pressure or metabolic parameters and without ischemia.
ALT-711 did not improve flow-mediated remodeling in
one-year old ZDF rats
Type 2 diabetes reduced the capacity of the endothelium
to induce vasodilatation, especially in resistance arteries
[31]. Likewise, in order to restore endothelium-dependent
dilation and hopefully local blood flow, vasodilator treat-
ments, drugs improving insulin sensitivity and exercise are
commonly recommended to diabetic patients. These
treatments and exercise are expected to increase eNOS
expression, which is, at least in part, the consequence
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Figure 8 Flow-mediated remodeling after treatment with TEMPOL: Changes in diameter (A,B) in response to stepwise increases in
pressure in HF and NF mesenteric resistance arteries isolated from lean Zucker (LZ, A) and diabetic fatty Zucker rats (ZDF, B) treated
with TEMPOL. Concentration-response curves to acetylcholine were performed in NF (C) and HF (D) arteries in the presence or absence of
L-NAME (100 μmol/L). Emax for acetylcholine-mediated relaxation (E) and the inhibitory effect of L-NAME on acetylcholine-mediated relaxation
(F) were calculated from the curves shown in C and D. Mean ± SEM is presented (n = 10 per group). *P < 0.05, HF arteries compared to NF
arteries. #P < 0.05, ZDF compared to LZ.
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http://www.cardiab.com/content/13/1/55of the chronic rise in blood flow as shear stress is a major
physiological stimulus for eNOS expression [4,25]. In a
previous study of mesenteric arteries in young ZDF rats,
we have shown that, despite no change in blood glucose
level, ALT-711 increased eNOS expression and MMPs ac-
tivity in association with a strong reduction in AGEs level.All together, these effects improved outward remodeling
and endothelium-mediated dilation [6]. In the present
study, performed in 12-month-old ZDF rats, ALT-711,
alone or combined with the antioxidant TEMPOL, did
not improve eNOS expression level, MMPs activity and
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Figure 9 Flow-mediated remodeling after treatment with ALT-711 and TEMPOL: C hanges in diameter (A,B) in response to stepwise in-
creases in pressure in HF and NF mesenteric resistance arteries isolated from lean Zucker (LZ, A) and diabetic fatty Zucker rats (ZDF, B)
treated with TEMPOL and ALT-711. Concentration-response curves to acetylcholine were performed in NF (C) and HF (D) arteries in the
presence or absence of L-NAME (100 μmol/L). Emax for acetylcholine-mediated relaxation (E) and the inhibitory effect of L-NAME on
acetylcholine-mediated relaxation (F) were calculated from the curves shown in C and D. Mean ± SEM is presented (n = 10 per group). *P < 0.05, HF ar-
teries compared to NF arteries.
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rats. This result might not be directly related to age
per se because in 12-month-old LZ rats, ALT-711 and
ALT-711 plus TEMPOL improved outward remodel-
ing. This is most likely due to the action of ALT-711
on AGEs level as TEMPOL alone had no effect. Fur-
thermore, in 24-month-old non-diabetic rats, hydral-
azine also improved flow-mediated outward remodeling
[32] suggesting that the pathway involved in flow-mediated
outward remodeling of resistance arteries remains relativelyintact in old rats. A possible explanation is that AGEs
cross-links are more stable over time and that ALT-711
cannot reverse preexisting cross-links after long-term ex-
posure to high glucose. Although this assumption remains
speculative, several experiments performed in the present
study support this hypothesis. Consequently, MMPs activa-
tion remained impossible in old ZDF rats and diameter ex-
pansion in response to high flow could not take place,
although the dose of ALT-711 used in the present study
























































9                8                7               6                7               
SNP (-LogM)
SNP (-LogM)
Figure 10 Vascular response to sodium nitroprusside: Cumulative
concentration–response curves to sodium nitroprusside (SNP)
obtained in NF (A) and HF (B) arteries isolated from LZ rats or ZDF
rats treated or not with ALT-711, TEMPOL or TEMPOL+ALT-711.
Mean ± SEM is presented (n = 10 rats per group).
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pilot study (Figure 11) without reducing significantly AGEs
level in the vascular wall. In agreement with our finding, in
old hypertensive dogs with high level of AGEs, it has been
shown that ALT-711 failed to reduce cardiac AGEs con-
tents although it slightly improved cardiac function [33].
Protective effect of ALT-711 in non-diabetic one-year old
rats
On the other hand, in the present study we found that
in non-diabetic old rats AGEs content in mesenteric re-
sistance arteries was significantly reduced by the com-
bination of ALT-711 plus TEMPOL. AGEs level was
much lower in old LZ rats than in old ZDF rats. In parallel,
this combined treatment also improved flow-mediated re-
modeling in LZ rats. Accordingly, ALT-711 continued to
be capable of reducing AGE cross-links in aging and con-
sequently improve vascular remodeling and function as
previously shown in large arteries [34,35]. Similarly, ALT-
711 therapy in non-diabetic elderly monkeys improvesimpaired cardiovascular function associated with aging or
hypertension [36]. These studies are in agreement with our
present work showing that ALT-711 improved outward re-
modeling of resistance mesenteric arteries in LZ rats with
a moderate arterial AGEs level. This is of significant inter-
est as rats were aged one year, which represents half their
lifespan. Certainly, the fact that remodeling is lost in 1-year
old rats is in agreement with the observations showing that
the incidence of cardiovascular events increases in
men aged 40 and over or in postmenopausal women
[37]. The chronic increase in blood flow restores
shear-stress-induced activation of eNOS and antioxi-
dant ability in aged arteries [38] despite an absence of
increase in arterial diameter (present study).
Antioxidant property of ALT-711 and protection of the
endothelium
Although it was unable to restore flow-mediated outward
remodeling, ALT-711 improved acetylcholine-dependent
relaxation in both NF and HF mesenteric resistance arter-
ies in ZDF rats. Although ALT-711 did not affect eNOS
expression level, it reduced oxidative stress. Certainly, in
ZDF rats, p67phox expression level was increased whereas
MnSOD and CuZnSOD levels were decreased. At the
same time, in NF and HF arteries in ZDF rats, acute treat-
ment with catalase and SOD improved acetylcholine-
mediated relaxation suggesting that oxidative stress
contributed mainly to the endothelium dysfunction, in
agreement with previous studies [4,39,40]. Certainly,
oxidative stress is a major cause of reduced NO bio-
availability leading to a reduction in endothelium-
mediated relaxation [40]. This was confirmed in the
present study using a chronic treatment with TEM-
POL, which improved endothelium (NO)-mediated re-
laxation in ZDF rats, although it remained below
control (lean rats) level. The chronic treatment with
AL-T711 had a similar effect on endothelium (NO)-
mediated relaxation reinforcing the assumption that
the beneficial effect of ALT-711 was mediated by an in-
trinsic antioxidant property. Furthermore, ALT-711 re-
duced p67phox level in ZDF rat arteries without
reduction in AGEs level. The combination of ALT-711
plus TEMPOL totally restored acetylcholine-mediated
relaxation to control level. Our observations are in
agreement with a work performed by Su et al. showing
a link between AGEs and oxidative stress in resistance
artery endothelial dysfunction in type 2 diabetic mice
[12]. Although ALT-711 did not affect AGEs level in
arteries isolated of ZDF rats, the present study did not
take into account the level of methylglyoxal which is
highly increased in diabetes [41] and which has a key
role in diabetes-associated endothelial dysfunction. In-
deed, excessive methylglyoxal production impairs trans-
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Figure 11 Detection of advanced glycation end-products in mesenteric arteries: Detection of advanced glycation end-products (AGEs)
using Western-blot analysis in mesenteric resistance arteries isolated from ZDF or LZ rats treated with ALT-711 (35 mg/kg per day),
ALT-711 (35 mg/kg per day) + TEMPOL (B) or the solvent (control). In another series of experiments (C), rats were treated with ALT-711
(10 mg/kg per day) or ALT-711 (100 mg/kg per day). Molecular weight (MW) is shown along the blots. Values are presented as mean ± SEM,
n = 10 rats per group (panel A and B). For panel C all the measurements are shown. *P < 0.05, ZDF versus LZ. #P < 0.05, treatment versus control.
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diabetes [43].
Physio-pathological consequences
As in young rats, AGEs in old ZDF rats might prevent
diameter enlargement in response to a chronic increase
in blood flow in addition to inducing endothelial dys-
function. Nevertheless, as the AGE breaker ALT-711,alone or in combination with the antioxidant TEMPOL,
failed to reduce the level of AGEs and to restore outward
remodeling in old ZDF rats arteries, such a conclusion
cannot be directly derived from our data. Nevertheless, we
can assume, based on our previous study in young rats
[10], that this is probable as the level of AGEs in
the present study is higher than in young rats. Interest-
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Figure 12 Measurement of MMPs activity in mesenteric arteries: MMPs activity was measured using in situ zymography performed in
arterial thin sections submitted to angiotensin II (angII) or not (control or Cont). Gelatinase activity was visualized as an enhanced
fluorescence of a fluorogenic gelatin substrate in mesenteric arteries using confocal microscopy. Arteries were isolated from LZ rats or from ZDF
rats treated or not with ALT-711, TEMPOL or TEMPOL + ALT-711. Bargraph: Quantification of gelatinolytic activity was performed using image
density analysis (3–4 arterial sections per artery and 6 rats per group). Mean ± SEM is presented. *P < 0.05, Angiotensin II versus control.
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finding may be of importance when recommending ex-
ercise or when prescribing vasodilator treatments to
diabetic patients. Indeed, both aim to induce flow-mediated
outward remodeling and to improve endothelium-mediated
dilation [44-46]. Although AGEs-breaking represents an
important way of reducing ischemic disorders associated
with diabetes, so far preventing their formation remains the
best if not the only way, to reduce cross-links in advanced
diabetes.Finally, in one-year-old LZ rats, ALT-711 alone or in
association with TEMPOL improved outward remodel-
ing. Accordingly, AGEs-breaking has a potential role in
the therapeutic arsenal in cardiovascular diseases in
older patients. Improving the response of resistance ar-
teries to shear stress is a key issue in ischemic disorders
and whether ageing is associated or not with diabetes
AGEs-breaking tools may improve local blood flow due
to their effect on outward remodeling and endothelium-
mediated dilation.
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We found that the AGE-breaker ALT-711 did not im-
prove outward remodeling in mature ZDF rats although
it remained able to reduce oxidative stress and improve
endothelium-dependent relaxation. On the other hand,
in mature non-diabetic rats, ALT-711 reduced AGEs
level and consequently improved outward remodeling.
Thus, AGEs breaking, at least using ALT-711, could be a
useful therapeutic tool in ageing with antioxidant prop-
erties in diabetes and with the capacity to improve out-
ward remodeling in non-diabetic subjects.
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